1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Handa Pharmaceuticals Inc

Handa Pharmaceuticals Inc

TTPEX:6620
139.00
TWD
+5.50
(+4.12%)
3.00EPS
31.39P/E
15.46BMarket Cap
Nov 13Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.11
- -
2.05
4.94
0.87
0.75
0.24
0.24
1.57
8.24
5.91
11.19
7.48
Basic EPS, GAAP
-0.73
-1.7
0.28
2.69
-1.55
-1.58
-2.37
-2.07
-0.32
5.41
3.37
4.85
3.03
Free Cash Flow per Basic Share
-1.21
-1.54
-1.5
4.19
-1.77
-2.09
-2.66
-1.56
-1.69
4.97
3.49
1.47
3.91
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1.53
- -
Book Value per Share
8.96
-6.92
5.33
7.68
6.21
6.92
4.53
3.71
5.45
19.54
22.19
33.59
30.9
Tangible Book Value per Share
7.09
-6.92
4.75
7.17
5.85
6.58
4.24
3.42
5.18
19.28
15.41
29.04
26.59
Basic Weighted Avg Shares
15
75
103
109
107
113
119
120
126
134
140
154
162
Sales/Revenue/Turnover
2
- -
211
538
94
84
29
29
198
1,106
831
1,729
1,211
Operating Margin (%)
-661.58
- -
10.32
53.78
-212.12
-243.77
-1,100.1
-868.42
-44.58
62.68
50.33
54.02
37.48
Depreciation Expense
3
3
6
8
7
18
56
35
15
12
10
164
165
Net Income, GAAP
-11
-128
29
293
-167
-178
-282
-248
-40
727
473
750
490
Effective Tax Rate (%)
- -
- -
12.43
2.04
- -
- -
- -
- -
- -
8.28
1.34
19.98
20.05
Profit Margin (%)
-658.07
- -
13.56
54.5
-177.72
-211.42
-977.53
-847.17
-20.24
65.7
56.91
43.36
40.48
Working Capital
111
-121
463
751
560
666
371
285
548
2,505
1,864
4,194
3,706
LT Debt
- -
- -
- -
- -
- -
12
6
6
19
8
33
37
31
Total Equity
154
-119
579
837
676
822
539
463
721
2,756
3,117
5,660
5,023
Return on Invested Capital (%)
- -
- -
8.08
38.68
- -
- -
- -
- -
- -
34.89
13.63
16.84
7.7
Return on Capital (%)
- -
- -
13.84
41.42
- -
- -
- -
- -
- -
41.31
15.97
16.95
10.56
Return on Common Equity (%)
- -
- -
- -
41.41
-22.01
-23.73
-41.47
-49.43
-6.76
41.81
16.1
17.08
10.6

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
10
10
10
LT Borrowings
- -
- -
- -
LT Finance Leases
37
36
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
169
167
163
Market Capitalization
14,494
11,491
15,457

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,312
4,291
4,171
Cash, Cash Equivalents & STI
3,706
3,769
3,730
Accounts Receivable, Net
580
477
366
Inventories
- -
- -
- -
Total Current Liabilities
118
482
465
Payables & Accruals
- -
- -
- -
ST Debt
10
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-15.66%
83.71%
81.58%
Free Cash Flow
-96.9%
-104.35%
-53.75%
Net Income, GAAP
-127.76%
-397.83%
58.6%
Sales/Revenue/Turnover
- -
224.07%
108.17%
Total Cash Common Dividend
- -
- -
67.48%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
217
216
210
188
831
2025
181
759
490
300
1,729
2026
210
212
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.83
0.73
1.05
0.76
3.37
2025
0.31
2.05
1.34
1.09
4.85
2026
0.46
0.19
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1.53
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Fang-Yu Liu
Full Time Employees
15
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.23, Nanke 3rd Road Tainan TQ Taiwan 744094
IPO Date
Dec 28, 2016
Website
handapharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Handa Pharmaceuticals, Inc. (6620.TWO) is a Taiwan-based specialty pharmaceutical company that develops and commercializes niche prescription drugs, high-barrier generics, and 505(b)(2) applications targeting the United States and other international markets. Founded in 2014 and headquartered at 3F-1 & 3F-2, No. 23, Nanke 3rd Road, Tainan City, Taiwan, the company operates from the Southern Taiwan Science Park as its global R&D center, with a focus on controlled-release technologies and difficult-to-formulate products for neuroscience, oncology, gastroenterology, and related therapeutic areas; its marketed products include PHYRAGO (dasatinib tablets for chronic myeloid leukemia, marketed by Handa Therapeutics, LLC), TASCENSO ODT (for multiple sclerosis, marketed by Cycle Pharmaceuticals), Dexlansoprazole Delayed-Release Capsules (for erosive esophagitis and non-erosive gastroesophageal reflux disease, marketed by Par Pharmaceutical), and Quetiapine Fumarate Extended-Release Tablets (for schizophrenia, bipolar disorder, and sleep disorders, marketed by Par Pharmaceutical and partners). The company pursues a dual-engine strategy of high-barrier/patentable generics and innovative 505(b)(2) drugs, with products primarily sold in the United States, Canada, and India, and ongoing pipeline developments including ONCORE proprietary oncology drug delivery technology, HND-033 and HND-027 for oncology, HND-004 for diabetes, HND-032 for smoking cessation, and HND-026 for gastrointestinal indications; it listed on the Taipei Exchange's emerging market in December 2016. In recent developments, Handa collaborates with Easywell Group and added a new partner for project HND-045 in 2024, aims to launch one new drug annually through its dual strategy, and maintains partnerships with Cycle Pharmaceuticals and Par Pharmaceutical for product commercialization, while pursuing expansion in the US and China markets as of 2025.